MedTrace Logo

The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia

NCT04422678 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-06-09

No results posted yet for this study

Summary

A randomized controlled pilot study on the safety \& efficacy of imatinib for the treatment of patient with moderate to severe SARS-COV-2 induced pneumonia.

Conditions

Interventions

DRUG

Imatinib Mesylate

Adding treatment by imatinib oral tablet into the standard treatment for moderate to severe COVID-19 pneumonia.

DRUG

Standard of Care

Standard of Care for the Moderate to Severe COVID-19 Pneumonia as per the Egyptian National Protocol by the Ministry of Health.

Sponsors & Collaborators

  • Science, Technology & Innovation Funding Authority (STIFA), Egypt

    collaborator UNKNOWN

  • Alexandria University

    lead OTHER

Principal Investigators

  • Hany ASSAAD, MD, PhD · University of Alexandria

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2020-09-30
Completion
2020-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04422678 on ClinicalTrials.gov